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 Abstract 
  Background/Aims:  Nephropathic cystinosis (NC) is a severe systemic disease and cysteamine 
improves its prognosis. Lysosomal cystine accumulation is the hallmark of cystinosis and is re-
garded as the primary defect due to mutations in the   CTNS   gene. However, there is great evi-
dence that cystine accumulation itself is not responsible for all abnormalities observed in NC. 
Studies have demonstrated altered ATP metabolism, increased apoptosis, and cell oxidation. An 
increased number of autophagosomes and autophagic vacuoles have been observed in cys-
tinotic fibroblasts and renal epithelial cells, suggesting that altered autophagy plays a role in 
NC, leading to increased production of reactive oxygen species. Therefore, cystinosis patients 
can be more susceptible to oxidative stress (OS) and it can contribute to the progression of the 
renal disease. Our goal was to evaluate a marker of OS (serum TBARS) in NC children, and to 
compare the results with those observed in healthy controls and correlated with renal function 
parameters.   Methods:  The study included patients aged under 18 years, with good adherence 
to the treatment and out of renal replacement therapy. The following parameters were evalu-
ated: serum creatinine, BUN, creatinine clearance estimated by stature and serum TBARS levels. 
  Results:  We selected 20 patients aged 8.0  8   3.6 years and observed serum TBARS levels of 4.03 
  8   1.02 nmol/ml. Serum TBARS levels in the 43 healthy controls, aged 7.4  8   1.1 years, were 1.60 
  8   0.04 nmol/ml. There was a significant difference between the plasma TBARS levels among 
the 2 groups (p   !   0.0001). We detected no significant correlation between plasma TBARS levels 
and renal function.  Conclusion:  An increased level of serum TBARS in patients with NC was ob-
served and this abnormality was not correlated with the renal function status degree. This is the 
first report that shows increased oxidative stress in serum of NC patients.     
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 Introduction 
  Nephropathic cystinosis is a severe systemic progressive disease. It involves several or-
gans throughout life. First, the kidneys are affected by proximal tubular dysfunction and 
Fanconi’s syndrome. During childhood, there is also frequent hypothyroidism and ocular 
involvement, leading to photophobia. Renal glomerular damage generally becomes apparent 
between 2 and 5 years of age and results in end-stage renal disease between 9 and 10 years of 
age, unless treatment with a cystine-depleting drug, cysteamine, is initiated early in life   [1]  . 
Patients without this treatment, besides presenting glomerular damage and chronic renal 
insufficiency, can also present pancreatic problems, e.g. diabetes mellitus and high levels of 
amylase, hepatic involvement, gastrointestinal complications, e.g. vomiting or gastric ulcers, 
muscular wasting and weakness, and various degrees of central nervous system involvement 
  [1, 2]  . However, although lysosomal cystine accumulation is the hallmark of cystinosis and 
is regarded as the primary defect due to mutations in the   CTNS   gene, there is great evidence 
that cystine accumulation itself is not responsible for all abnormalities observed in cystino-
sis. Several studies have recently demonstrated altered ATP metabolism, increased apoptosis, 
and cell oxidation. For the most part, these abnormalities were observed using cell models 
and are not necessarily mutually exclusive   [3]  . Moreover, an increased number of autopha-
gosomes and autophagic vacuoles have been observed in cystinotic fibroblasts and renal 
epithelial cells, suggesting that altered autophagy also plays a role in cystinosis   [4]  . These 
observations were associated with structural mitochondrial abnormalities and increased 
production of reactive oxygen species (ROS). Taken together, these findings suggest that cys-
tinosis patients can be more susceptible to oxidative stress, which can contribute to the pro-
gression of renal disease in cystinosis patients even when they show a good response to treat-
ment with cysteamine   [5, 6]  .
  Our aim was to evaluate a marker of oxidative stress in pediatric cystinosis and compare 
the results obtained in cystinotic children with those observed in healthy normal controls. 
We also correlated the oxidative stress marker with renal function parameters in these pa-
tients. Of note, this is the first documentation of increased oxidative stress in the serum of 
cystinotic patients.
  Patients  and  Methods 
 Patients 
 The study cohort was selected from cystinosis patients aged  ! 18 years. Inclusion criteria 
were parental consent for participation in the study and good adherence to the treatment, 
including their attendance at the follow-up examinations and clinical evaluations, and no 
renal replacement therapy. Only patients with chronic kidney disease (CKD) in stage 1–4 
(based on KDOQI guidelines   [7]  ) were included.
    All patients selected had taken cysteamine at a recommended dosage of 60–90 mg/kg/
day   [5]  . Sample collections to measure the parameters of the study were done at the time 
when patients were under metabolic and electrolyte control, and free of infections.
  M e t h o d s  
  The following renal function parameters were evaluated: serum creatinine, BUN and 
creatinine clearance estimated by the Schwartz formula   [8]  .
    Serum levels of thiobarbituric acid-reactive substances (TBARS), which are markers of 
lipid peroxidation, were determined using the TBARS assay. In brief, 0.2 ml of serum sam-
ple was diluted in 0.8 ml of distilled water. Immediately thereafter, 1 ml of 17.5% trichloro-75
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acetic acid was added. Following the addition of 1 ml of 0.6% thiobarbituric acid, pH 2, the 
sample was placed in a boiling water bath for 15 min, after which it was allowed to cool. 
Subsequently, 1 ml of 70% trichloroacetic acid was added, and the mixture was incubated 
for 20 min. The sample was then centrifuged for 15 min at 2,000 r.p.m. The optical density 
of the supernatant was read at 534 nm against a reagent blank using a spectrophotometer. 
The quantity of TBARS was calculated using a molar extinction coefficient of 1.56   !   10 5  
  M   –1   cm –1 .
  Serum levels of TBARS (expressed as nmol/ml  [9] ) were compared between patients and 
healthy controls, and associations between this parameter and parameters of renal function 
were assessed.
  Statistical  Analysis 
  Homogenous data are expressed as means   8   SD, and non-homogenous data are ex-
pressed as medians (interquartile ranges). The independent sample t test was employed to 
compare serum levels of TBARS between the patients and healthy control children, and Pear-
son’s correlation coefficient was used to correlate serum TBARS with renal function param-
eters. This study was approved by the local ethics committee. Informed consent was obtained 
from the parents of all children for participation in this study.
  R e s u l t s  
 We selected 20 cystinosis patients (6 females) aged 8.0  8  3.6 years (mean  8  SD) in CKD 
stage 1–4 with good adherence to the treatment comprising cysteamine. The distribution of 
the patients according to CKD stage is shown in  table 1 . The dosage of cysteamine was 72.06 
  8   5.22 mg/kg/day and was divided every 6 h.
      Table 2   shows the results found in these cystinosis patients. In the 43 healthy controls 
aged 7.4  8  1.1 years (mean  8  SD), serum levels of TBARS were 1.60  8  0.04 nmol/ml (mean 
  8  SD); in cystinosis patients, serum TBARS levels were 4.03  8  1.02 nmol/ml (mean  8  SD). 
There was no statistical difference between patients and healthy controls regarding age, but 
Table 1. Cystinosis patients (n = 20) according to CKD stage
CKD stage 1 9 patients
CKD stage 2 5 patients
CKD stage 3 5 patients
CKD stage 4 1 patient
Table 2.   Parameters measured in the 20 cystinosis patients 
Serum creatinine, mol/l
Median 
Interquartile range
Geometric mean, log transformed
59.5 
39.6–93.0
61.0
BUN, mmol/l 10.385.7
eGFR (Schwartz formula), ml/min/1.73 m2 84.0841.5
Serum TBARS, nmol/ml 4.0381.0276
Nephron Extra 2011;1:73–77
 DOI:  10.1159/000331445 
EXTRA
  Vaisbich et al.: Oxidative Stress in Cystinosis 
www.karger.com/nne
    © 2011 S. Karger AG, Basel
  Published online: September 19, 2011 
there was a significant difference between the plasma TBARS levels between both groups
(p   !   0.0001).
    To determine the effect of renal function impairment on serum TBARS, we correlated 
this parameter with serum creatinine, BUN, creatinine clearance estimated by stature and 
CKD stage. No significant correlations between plasma TBARS and all these parameters 
were detected (  fig. 1  ).
  Discussion 
 Nephropathic cystinosis is a severe disease. Although cysteamine treatment improves its 
prognosis, renal failure is not completely abolished. Gahl et al.   [6]   emphasized that cyste-
amine is not 100% effective, even taking all appropriate steps, since some patients present 
extrarenal complications and renal failure at the age of 20 years. Likewise, Greco et al.   [10]   
have also demonstrated that end-stage renal failure cannot be prevented in most patients but 
is only postponed to the 2nd or 3rd decade of life; late-onset complications ultimately de-
velop in a substantial proportion of patients. Ergo, nephropathic cystinosis remains a chal-
lenge for the treating physician.
    Recently, several studies have demonstrated altered ATP metabolism, and increased 
apoptosis and cell oxidation in cystinosis   [3]  . In addition, increased autophagy is involved 
leading to increased ROS production   [4]  . Most of the studies have been conducted in cell 
  Fig. 1.  Correlation between plasma TBARS and serum creatinine (  a ,  c ), BUN (  b ) and creatinine clearance 
estimated by stature [eGFR (Schwartz formula);   d  ] in nephropathic cystinosis patients.   a   r = –0.04, p = 
0.86.   b   r = 0.02, p = 0.93.   c   r = –0.10, p = 0.65.   d   r = 0.17, p = 0.46. 77
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models, but a study assessing oxidative stress in the serum of the patients has not been pub-
lished to date. Therefore, our aim was to evaluate serum TBARS levels in pediatric cystinosis 
patients. Using this simple methodology, we observed that plasma TBARS, a biomarker of 
oxidative stress, was increased in patients with nephropathic cystinosis. The balance be-
tween oxidants and antioxidants is considerably distorted in patients with chronic renal in-
sufficiency. Evidence suggests that ROS are not merely the consequence of treatment or pro-
gressing disease but also one of the causal agents of chronic renal impairment, and that oxi-
dative stress can occur even in the absence of hemodialysis. Patients with uremia have 
diminished response to oxidative stress probably due to a decrease in the antioxidant capac-
ity; the mechanisms underlying this decrease, however, remain to be elucidated   [11]  . How-
ever, in this study, we could not correlate TBARS levels with creatinine clearance, CKD stage, 
serum creatinine or BUN. Therefore, in cystinosis patients oxidative stress could be a result 
of the intrinsic mechanism of the disease   [3]  . Oxidative stress results in the formation of 
highly reactive and unstable lipid hydroperoxides, and decomposition of unstable peroxides 
derived from polyunsaturated fatty acids results in the formation of malondialdehyde, which 
is measured by the TBARS assay. However, a drawback of this assay is that there may be 
other sources of malondialdehyde. Thus, this test is not specific for lipid peroxidation.
    The limitations of our study are the small number of patients and the fact that TBARS 
is not the best oxidative stress marker. Although this is only a pilot study, it is of paramount 
importance since it is the first report proving that oxidative stress is increased in the serum 
of patients with cystinosis independent of the state of renal function. Therefore, we intend to 
assess more specific markers in future studies. 
    This knowledge may have implications on the treatment of cystinosis patients, since 
oxidative stress is involved in the progression of renal disease, especially in these patients 
 [11] . 
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